

RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*), GRIFOLS, S.A. (the “**Company**”) informs that the Company Talecris Biotherapeutics Holdings (“**Talecris**”) has filed with the Securities and Exchange Commission (SEC) of the United States a preliminary version of Form F-4 in connection with the acquisition of 100% of the share capital of Talecris by Grifols.

In Barcelona, on the 10th August 2010

Raimon Grifols Roura
Secretary to the Board of Directors